Translational Imaging Innovations (TII) was founded with the mission to streamline ocular research by developing integrated imaging software platforms. The company's vision is to accelerate the timeline of ocular innovations, making breakthroughs more accessible and cost-effective. TII offers a suite of products, including Lattice, Oculink, Ocuvault, and Mosaic, designed to enhance the collection, curation, and collaboration of images and data in ophthalmic research and clinical trials. Their market focus is on ophthalmology and vision science investigators, providing a collaborative and secure environment for research.

Notable affiliated individuals include experts in imaging science and ophthalmology, although specific names are not provided. TII has attracted attention from investors interested in medical technology advancements. Key achievements include the development of their Integrated Translational Imaging® platform, which has significantly reduced the frustration and costs associated with transferring image-based medical breakthroughs to clinical settings. Overall, TII has made a substantial impact by improving the efficiency and effectiveness of ocular research workflows.